Revenue in treating serious disease
99%- TRIKAFTA/KAFTRIO (counted)86%
- ALYFTREK (counted)7%
- Other cystic fibrosis medicines (KALYDECO, ORKAMBI, SYMDEKO/SYMKEVI) (counted)5%
- CASGEVY (counted)1%
- JOURNAVX0.5%
- Other revenues0.3%
Cystic fibrosis medicines and CASGEVY, for sickle cell disease, count. JOURNAVX, a pain medicine, does not.
Price against value
No margin of safetyPrice 93% above base case · price Friday 20th November 2026